ReviewExpert opinion on biological therapy2009
Treating autoimmune disease by targeting CD8(+) T suppressor cells.
Review in Expert opinion on biological therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Characterization of novel CD8Cellular and molecular life sciences : CMLS · 2024Article
- The Role of Innate Immunity in Osteoarthritis and the Connotation of "Immune-joint" Axis: A Narrative Review.Combinatorial chemistry & high throughput screening · 2024Review
- CD8Frontiers in immunology · 2024Article
- Antigen perception in T cells by long-term Erk and NFAT signaling dynamics.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- CD8International journal of molecular sciences · 2022Review
- Balneotherapy year in review 2021: focus on the mechanisms of action of balneotherapy in rheumatic diseases.Environmental science and pollution research international · 2022Review
- CD8+ T-Cells in Juvenile-Onset SLE: From Pathogenesis to Comorbidities.Frontiers in medicine · 2022Review
- Openness weighted association studies: leveraging personal genome information to prioritize non-coding variants.Bioinformatics (Oxford, England) · 2021Article
- Article
- CD8Frontiers in immunology · 2020Review
- Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.CNS drugs · 2017Review
- Loss of Immune Tolerance Is Controlled by ICOS in Sle1 Mice.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Molecular and Cellular Characterization of Human CD8 T Suppressor Cells.Frontiers in immunology · 2016Review
- Eye-mediated immune tolerance to Type II collagen in arthritis-prone strains of mice.Journal of cellular and molecular medicine · 2014Article
- CD8⁺ cells regulate the T helper-17 response in an experimental murine model of Sjögren syndrome.Mucosal immunology · 2014Article
- 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.Mediators of inflammation · 2014Article
- Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.Clinical immunology (Orlando, Fla.) · 2013Article
- Phenotypic changes in immune cell subsets reflect increased infarct volume in male vs. female mice.Translational stroke research · 2013Article
- Eye-mediated induction of specific immune tolerance to encephalitogenic antigens.CNS neuroscience & therapeutics · 2013Article
- CD8+CD45RA+CCR7+FOXP3+ T cells with immunosuppressive properties: a novel subset of inducible human regulatory T cells.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Current treatments for autoimmune disease are hampered by the non-specificity of immunomodulatory interventions, having to accept broad suppression of immunoresponsiveness with potentially serious side effects, such as infection or malignancy. The development of antigen-specific approaches, downregulating pathogenic immune responses while maintaining protective immunity, would be a major step forward. One possible approach involves the targeting of physiological regulatory mechanisms, such as inhibitory CD8 T cells that are now recognized to fine-tune many aspects of immune responses. CD8 T suppressor (Ts) cells may directly inhibit other T cells or condition antigen-presenting cells in such a way that immune amplification steps are dampened. The promise of CD8 Ts cells lies in their potential to disrupt host-injurious immune responses in a targeted fashion. For therapeutic purposes, such CD8 Ts cells could either be generated in vitro and transferred into the host or their numbers and activity could be modulated by treating the patient with established or novel immunomodulators. Emerging evidence shows that several subsets of CD8 Ts cells exist. While there is still considerable uncertainty about the molecular mechanisms through which CD8 Ts cells can reset immune responses to protect the host, their potential diagnostic and therapeutic use is intriguing and has generated renewed interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.